Case studies

Revolver

Revolver Therapeutics is at the forefront of a revolution in cancer treatment. By targeting transcription factors with innovative peptide-based therapeutics, the company is opening a new frontier in addressing previously untreatable cancers. With UKI2S backing and a clear focus on delivering impactful solutions, Revolver is poised to make a lasting difference in the fight against childhood gliomas and beyond.

Antiverse

Antiverse is a techbio company designing antibodies for challenging drug targets like G-protein-coupled receptors (GPCRs) and ion channels. Embedded in cell membranes, GPCRs are difficult to purify– an essential step required to design antibodies against them.

iFAST Diagnostics

Every year, antimicrobial resistance (AMR) claims the lives of over a million people globally. The delay in effective diagnosis is a major contributing factor, as traditional Antimicrobial Susceptibility Testing (AST) methods take 48-72 hours to yield results.

twig

From food ingredients to personal care products, many of the products and services we rely on day to day are powered by fossil fuels and intensive farming. Unfortunately this is no longer sustainable — if we’re to meet the challenges of global warming and achieve net zero.

Zentraxa

Vitarka

Solasta Bio

Revona Bio

Resurrect Bio

Pencil Biosciences

NKIO

Ikarovec

iFAST Diagnositcs

HutanBio

Glialign

Bitrobius

Antiverse

Synthace

Biology will change the world. With it, we can feed, heal, and fuel people for generations to come. But enroute to these novel products, the research and development is complex, risky and costly.